Clinical Trials Logo

Filter by:
NCT ID: NCT00685607 Completed - Diarrhea Clinical Trials

Study to Determine the Best Way to Measure How Quickly the Drug Can Give Relief From Sudden Diarrhea

Start date: October 2008
Phase: Phase 4
Study type: Interventional

For six hours following drug administration, subjects will rate the severity of specific symptoms. At the end of the six hour study, subjects will rate the overall effectiveness of the product.

NCT ID: NCT00683969 Completed - Clinical trials for Myasthenia Gravis, Generalized

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis

Start date: August 2004
Phase: Phase 3
Study type: Interventional

The efficacy and safety of CellCept (1g po, bid for 36 weeks) will be assessed in patients with myasthenia gravis receiving prednisone, or other corticosteroids. During the study, patients will undergo gradual corticosteroid dose reduction, if they respond to treatment. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00683917 Terminated - Uterine Fibroids Clinical Trials

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Start date: May 2008
Phase: Phase 2
Study type: Interventional

PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.

NCT ID: NCT00683878 Completed - Type 2 Diabetes Clinical Trials

Add-on to Thiazolidinedione (TZD) Failures

Start date: July 2008
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied

NCT ID: NCT00683657 Completed - Type 2 Diabetes Clinical Trials

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

Start date: July 2008
Phase: Phase 3
Study type: Interventional

This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone

NCT ID: NCT00683306 Approved for marketing - Clinical trials for Non Small Cell Lung Cancer (NSCLC)

Open Label Extension Study With Gefitinib (IRESSAâ„¢) for Completing Trial Patients Who May Benefit From Further Treatment

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of gefitinib established in their preceding study, for as long as the patients continue to derive benefit.

NCT ID: NCT00680901 Active, not recruiting - Clinical trials for Neoplasms, Gastrointestinal Tract

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Start date: June 4, 2008
Phase: Phase 3
Study type: Interventional

This is an international multi-center trial that will enroll patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors have amplification of the ErbB2 (HER2) gene. The trial will investigate whether lapatinib, when added to the chemotherapy regimen, capecitabine plus oxaliplatin (CapeOx), extends the time to progression and overall survival. Tumor ErbB2 (HER2) status must be known before trial entry. CapeOx is administered to all patients, and patients will be randomly assigned to receive either lapatinib or placebo.

NCT ID: NCT00679965 Completed - Clinical trials for Distal, Subungual Onychomycosis

Study of Different Doses of a Novel Treatment for Onychomycosis

Start date: February 28, 2006
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.

NCT ID: NCT00679939 Completed - Clinical trials for Diabetes Mellitus, Type 2

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

Start date: April 21, 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus

NCT ID: NCT00679588 Completed - Clinical trials for Venous Thromboembolism

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

SAVE-ABDO
Start date: April 2008
Phase: Phase 3
Study type: Interventional

The primary objective is to compare the efficacy and safety of once daily (q.d.) subcutaneous (s.c.) injections of Semuloparin sodium (AVE5026) with q.d. s.c. injections of Enoxaparin for the prevention of Venous Thromboembolic Events (VTE) in patients undergoing major abdominal surgery. The secondary objectives are to evaluate the safety of Semuloparin sodium (AVE5026) and to document Semuloparin sodium (AVE5026) exposure in this population.